Description:
This is a single-center cross-sectional imaging study in patients with localized lung cancer
undergoing immunotherapy with or without stereotactic radiation therapy as part of the
companion clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for
Non-Small Cell Lung Cancer). Each patient will undergo a single [18F]F-AraG PET exam as part
of this study. [18F]F-AraG will be administered at a single time point intravenously prior to
PET imaging. Whole-body PET will be acquired along with a whole body low dose CT (PET/CT)
used for attenuation correction and anatomic localization of [18F]F-AraG uptake, SUV
calculation, and volumetric selection for radiomic analyses.
Title
- Brief Title: T-Cell PET Imaging With [18F]F-AraG in Lung Cancer
- Official Title: T-Cell PET Imaging With [18F]F-AraG and Radiomics to Guide Combined Radiation and Systemic Immune Modulating Therapies
Clinical Trial IDs
- ORG STUDY ID:
176513
- SECONDARY ID:
NCI-2018-02158
- NCT ID:
NCT03311672
Conditions
- Non-small Cell Lung Cancer
Interventions
Drug | Synonyms | Arms |
---|
[18F]F-Ara-G | 2'-deoxy-2'-[18F]fluoro-9-β-Darabinofuranosylguanine | Cohort 1 - Immunotherapy Alone |
Pembrolizumab | Keytruda | Cohort 1 - Immunotherapy Alone |
Purpose
This is a single-center cross-sectional imaging study in patients with localized lung cancer
undergoing immunotherapy with or without stereotactic radiation therapy as part of the
companion clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for
Non-Small Cell Lung Cancer). Each patient will undergo a single [18F]F-AraG PET exam as part
of this study. [18F]F-AraG will be administered at a single time point intravenously prior to
PET imaging. Whole-body PET will be acquired along with a whole body low dose CT (PET/CT)
used for attenuation correction and anatomic localization of [18F]F-AraG uptake, SUV
calculation, and volumetric selection for radiomic analyses.
Detailed Description
This is a single-center cross-sectional imaging study in patients with localized lung cancer
undergoing immunotherapy with or without stereotactic radiation therapy as part of the
companion clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for
Non-Small Cell Lung Cancer). Each patient will undergo a single [18F]F-AraG PET exam as part
of this study. [18F]F-AraG will be administered at a single time point intravenously prior to
PET imaging. Whole-body PET will be acquired along with a whole body low dose CT (PET/CT)
used for attenuation correction and anatomic localization of [18F]F-AraG uptake, SUV
calculation, and volumetric selection for radiomic analyses.
A total of 20 patients will be enrolled over an accrual period of approximately 12 months.
Approximately 10 patients will be enrolled in the immunotherapy alone cohort and
approximately 10 patients will be enrolled in the immunotherapy and stereotactic radiation
therapy cohort.
Patients will be evaluated one day and one week via telephone after each radiopharmaceutical
injection for safety follow-up. All adverse events will be recorded. Due to the noninvasive
and non-therapeutic nature of the study, potential risks of the study are anticipated to be
low.
Trial Arms
Name | Type | Description | Interventions |
---|
Cohort 1 - Immunotherapy Alone | Experimental | Approximately 10 patients will be enrolled in the immunotherapy alone cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection. | - [18F]F-Ara-G
- Pembrolizumab
|
Cohort 2 - Immunotherapy with Stereotactic Radiation | Experimental | Approximately 10 patients will be enrolled in the immunotherapy with stereotactic radiation therapy cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection. | - [18F]F-Ara-G
- Pembrolizumab
|
Eligibility Criteria
Inclusion Criteria:
1. Age greater than or equal to 18 years
2. Histologically or cytologically documented stage I-IIIA non-small cell lung cancer
(NSCLC)
3. Eligible for with plan to undergo immunotherapy alone or both immunotherapy and
stereotactic radiation therapy as part of NCT03217071
4. In female patients, negative pregnancy test with no plans to become pregnant during
the duration of the study
5. Able to provide informed consent and follow the study guidelines
Exclusion Criteria:
1. Female patients who are pregnant or breastfeeding
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | The correlation between number of infiltrating CD3+ T cells/μm2 in the non-small cell lunger cancer thoracotomy specimen as quantified by immunohistochemistry and the activated T-cell concentration as determined by [18F]F-AraG PET (SUVmax) |
Time Frame: | Baseline (after two cycles of pembrolizumab) |
Safety Issue: | |
Description: | The correlation between number of infiltrating CD3+ T cells/μm2 in the non-small cell lunger cancer thoracotomy specimen as quantified by immunohistochemistry and the activated T-cell concentration as determined by [18F]F-AraG PET (SUVmax) |
Secondary Outcome Measures
Measure: | The detection of out-of-target radiation-mediated immune modulation in lymph nodes using [18F]F-AraG PET |
Time Frame: | Baseline (after two cycles of pembrolizumab) |
Safety Issue: | |
Description: | The detection of out-of-target radiation-mediated immune modulation in lymph nodes using [18F]F-AraG PET |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Withdrawn |
Lead Sponsor: | University of California, San Francisco |
Last Updated
October 21, 2019